-
PDF
- Split View
-
Views
-
Cite
Cite
Meghan A Baker, Kenneth E Sands, Susan S Huang, Ken Kleinman, Edward J Septimus, Neha Varma, Jackie Blanchard, Russell E Poland, Micaela H Coady, Deborah S Yokoe, Sarah Fraker, Allison Froman, Julia Moody, Laurel Goldin, Amanda Isaacs, Kacie Kleja, Kimberly M Korwek, John Stelling, Adam Clark, Richard Platt, Jonathan B Perlin, CDC Prevention Epicenters Program, The Impact of Coronavirus Disease 2019 (COVID-19) on Healthcare-Associated Infections, Clinical Infectious Diseases, Volume 74, Issue 10, 15 May 2022, Pages 1748–1754, https://doi.org/10.1093/cid/ciab688
- Share Icon Share
Abstract
The profound changes wrought by coronavirus disease 2019 (COVID-19) on routine hospital operations may have influenced performance on hospital measures, including healthcare-associated infections (HAIs). We aimed to evaluate the association between COVID-19 surges and HAI and cluster rates.
In 148 HCA Healthcare-affiliated hospitals, from 1 March 2020 to 30 September 2020, and a subset of hospitals with microbiology and cluster data through 31 December 2020, we evaluated the association between COVID-19 surges and HAIs, hospital-onset pathogens, and cluster rates using negative binomial mixed models. To account for local variation in COVID-19 pandemic surge timing, we included the number of discharges with a laboratory-confirmed COVID-19 diagnosis per staffed bed per month.
Central line-associated blood stream infections (CLABSI), catheter-associated urinary tract infections (CAUTI), and methicillin-resistant Staphylococcus aureus (MRSA) bacteremia increased as COVID-19 burden increased. There were 60% (95% confidence interval [CI]: 23–108%) more CLABSI, 43% (95% CI: 8–90%) more CAUTI, and 44% (95% CI: 10–88%) more cases of MRSA bacteremia than expected over 7 months based on predicted HAIs had there not been COVID-19 cases. Clostridioides difficile infection was not significantly associated with COVID-19 burden. Microbiology data from 81 of the hospitals corroborated the findings. Notably, rates of hospital-onset bloodstream infections and multidrug resistant organisms, including MRSA, vancomycin-resistant enterococcus, and Gram-negative organisms, were each significantly associated with COVID-19 surges. Finally, clusters of hospital-onset pathogens increased as the COVID-19 burden increased.
COVID-19 surges adversely impact HAI rates and clusters of infections within hospitals, emphasizing the need for balancing COVID-related demands with routine hospital infection prevention.
(See the Editorial Commentary by Gottlieb and Fridkin on pages 1755–6.)
The coronavirus disease 2019 (COVID-19) pandemic placed extraordinary demands on the healthcare system, resulting in modifications in routine patient care practices that could have the potential to either increase or decrease risks for healthcare-associated infections (HAIs). Negative impacts may have resulted when usual efforts to monitor and prevent HAIs were redirected to the COVID-19 response. Enhanced isolation practices and the burden of increased personal protective equipment (PPE) requirements may have led to reduced focus on routine HAI prevention activities such as central line and urinary catheter care. Earlier studies suggest that these shifts in activities and supplies could be associated with an increase in HAI rates [1, 2].
Simultaneously, infection prevention and control practices became more visible in healthcare systems. Hand hygiene was emphasized both inside and outside of healthcare facilities [3]. Training on donning and doffing of PPE was enhanced, and many hospitals saw increased compliance with contact precautions. It is possible that increased attention to standard infection prevention practices and the use of PPE impacted HAI rates in a beneficial direction, particularly the spread of multidrug-resistant organisms (MDROs) [4, 5].
Increased attention to infection prevention practices may have balanced the additional pandemic-related burden on infection prevention resources. Understanding whether and how COVID-19 impacted HAI rates is essential to guide resources, policies, and practices during the next stages of the COVID-19 response.
METHODS
Study Population and Setting
We conducted a prospective cohort study in 148 HCA Healthcare-affiliated hospitals. HAI events were assessed by the hospitals’ infection preventionists on all patients admitted between 1 March 2020 and 30 September 2020. Hospital-onset bloodstream infections (BSI) and MDRO events were assessed in 81 hospitals with microbiology data available between 1 March 2020 and 31 December 2020. We used a spatial and temporal scan statistic to identify clusters in 40 of those hospitals (Figure 1) [6–9]. The 40 hospitals were a random sample of the 81 hospitals, balanced on hospital and intensive care unit census, average comorbidity count, length of stay, and historical cluster data [10]. This study was approved by the Harvard Pilgrim Health Care institutional review board, and HCA Healthcare-affiliated hospitals and collaborating institutions delegated review.

Hospitals included in the analyses. NHSN infection analysis included 148 hospitals. In 81 hospitals, microbiology data were available and included in the BSI and MDRO analyses. A convenience subset of those hospitals was included in the cluster analysis (40 hospitals). Abbreviations: BSI, bloodstream infections; MDRO, multidrug-resistant organism; NHSN, National Healthcare Safety Network.
Data Sources and Events
Central line-associated blood stream infections (CLABSI), catheter-associated urinary tract infections (CAUTI), methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, and Clostridioides difficile infection (CDI) reported by participating hospitals to the Centers for Disease Control and Prevention’s (CDC) National Healthcare Safety Network (NHSN) were identified [11]. To validate the analyses based on NHSN data, microbiology data in a subset of the hospitals were used to identify any hospital-onset BSIs or MDRO-positive clinical cultures. MRSA bacteremia and CDI were reported directly to NHSN based on microbiology data and are thus not validated. Hospital-onset BSI was defined as a positive blood culture obtained on hospital day 3 or later and in an inpatient location. If the organism was on the NHSN list of common commensal organisms [12], we required 2 cultures of the same organism on the same or consecutive days. Hospital-onset MDROs were defined as clinical cultures growing an MDRO organism based on the CDC criteria [13] and obtained from any body site on hospital day 3 or later, excluding surveillance cultures. The MDRO analysis was also separated into MRSA, vancomycin-resistant enterococcus (VRE), and Gram-negative bacteria.
In 40 hospitals, we identified clustering of organisms based on hospitals’ microbiology data. Clusters were defined by statistically significant increases in organisms collected on hospital day 3 or later from a single ward or clinically related wards compared to a 2-year baseline time period [6]. Identification of clusters was based on matching of species and antimicrobial resistance profile when available. We used a statistically based cluster detection tool, WHONET-SaTScan, to identify clusters, and parameters were based upon prior studies [6, 14]. Statistical significance was measured using a recurrence interval, which estimates the likelihood that the cluster signal would occur by chance [15]. We used a threshold recurrence interval of 200 days, meaning that a cluster of this type of organism with the observed number and distribution of cases would be expected to occur by chance less than once per every 200 days.
For each facility and month, the number of COVID-19 patients per staffed bed was calculated by dividing the number of cases discharged from the facility with SARS-CoV-2, confirmed by polymerase chain reaction, per month by the number of beds the facility was approved to service. As we included COVID-19 patients discharged from facilities rather than admitted, we did not include lag time in the analysis. Covariates included hospital size as a categorical variable (small <200 beds, medium 200 to <300 beds, and large ≥300 beds). CLABSI and CAUTI models included the expected count as an offset, whereas MRSA bacteremia and CDI models included patient days as a covariate. We also evaluated chronologic calendar month to account for changes in process over time and use of contact precautions for MRSA and VRE in the models.
Statistical Analysis
We used negative binomial mixed models to account for within-hospital correlation across the repeated measures over time. Different models were developed for each event type. The data for the models included the monthly number of discharges of COVID-19 patients per staffed bed as the predictor. Results are presented as the relative rate in the event per 0.1 increase in the monthly discharges per staffed bed. Excess cases of HAIs were calculated as the difference between the observed number of events and the predicted number from the model, had there been 0 COVID-19 discharges across the study period. Facility level parameters limited to hospital size were included in the models. All statistical analyses were performed in SAS version 9.4.
Role of the Funding Source
This study was funded by the CDC Prevention Epicenter Program. The funder had no role in the design or conduct of the study; collection, management, analysis or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
RESULTS
The 148 hospitals ranged in size from 34 to 1013 beds and were located in 17 states. The hospitals had a total of 1 024 160 discharges between 1 March 2020 and 30 September 2020 (Table 1). They included 60 small facilities, 40 medium facilities, and 48 large facilities.
. | Number of Discharges in 148 NHSN Facilities (N = 1 024 160) . | . | Number of Discharges in 81 Facilities With Microbiology Data (N = 882 835) . | . |
---|---|---|---|---|
Patient characteristic . | N . | % . | N . | % . |
Age at admission | ||||
Mean | 50 | 51 | ||
Median (IQR) | 55 (31.0–72.0) | 56 (31.0–72.0) | ||
Age categorized | ||||
0–17 | 125 613 | 12.3 | 108 961 | 12.3 |
18–44 | 270 397 | 26.4 | 224 274 | 25.4 |
45–54 | 103 017 | 10.1 | 88 142 | 10.0 |
55–64 | 152 037 | 14.8 | 132 238 | 15.0 |
65–74 | 165 925 | 16.2 | 147 004 | 16.7 |
75–84 | 132 897 | 13.0 | 118 009 | 13.4 |
≥85 | 74 265 | 7.3 | 64 197 | 7.3 |
Age >65 | ||||
Yes | 373 087 | 36.4 | 329 210 | 37.3 |
Male | ||||
Yes | 459 221 | 44.8 | 394 537 | 44.7 |
Race categorized | ||||
Asian | 19 829 | 1.9 | 16 037 | 1.8 |
Asian Indian | 8383 | 0.8 | 6278 | 0.7 |
American Indian/ Alaska Native | 1461 | 0.1 | 1502 | 0.2 |
Black | 163 049 | 15.9 | 131 504 | 14.9 |
Hawaiian/Pacific Islander | 1253 | 0.1 | 930 | 0.1 |
White | 692 422 | 67.6 | 606 548 | 68.7 |
Other | 118 170 | 11.5 | 101 493 | 11.5 |
Unknown | 19 593 | 1.9 | 18 543 | 2.1 |
Hispanic/Latino | ||||
Yes | 181 966 | 17.8 | 136 414 | 15.5 |
Length of stay | ||||
Mean | 6 | 6 | ||
Median (IQR) | 4 (3.0–6.0) | 4 (3.0–6.0) | ||
Staffed beds | ||||
Mean | 344 | 363 | ||
Median (IQR) | 313 (231–417) | 315 (231–425) | ||
Elixhauser count | ||||
Mean | 3 | 3 | ||
Median (IQR) | 2 (1.0–4.0) | 2 (1.0–4.0) |
. | Number of Discharges in 148 NHSN Facilities (N = 1 024 160) . | . | Number of Discharges in 81 Facilities With Microbiology Data (N = 882 835) . | . |
---|---|---|---|---|
Patient characteristic . | N . | % . | N . | % . |
Age at admission | ||||
Mean | 50 | 51 | ||
Median (IQR) | 55 (31.0–72.0) | 56 (31.0–72.0) | ||
Age categorized | ||||
0–17 | 125 613 | 12.3 | 108 961 | 12.3 |
18–44 | 270 397 | 26.4 | 224 274 | 25.4 |
45–54 | 103 017 | 10.1 | 88 142 | 10.0 |
55–64 | 152 037 | 14.8 | 132 238 | 15.0 |
65–74 | 165 925 | 16.2 | 147 004 | 16.7 |
75–84 | 132 897 | 13.0 | 118 009 | 13.4 |
≥85 | 74 265 | 7.3 | 64 197 | 7.3 |
Age >65 | ||||
Yes | 373 087 | 36.4 | 329 210 | 37.3 |
Male | ||||
Yes | 459 221 | 44.8 | 394 537 | 44.7 |
Race categorized | ||||
Asian | 19 829 | 1.9 | 16 037 | 1.8 |
Asian Indian | 8383 | 0.8 | 6278 | 0.7 |
American Indian/ Alaska Native | 1461 | 0.1 | 1502 | 0.2 |
Black | 163 049 | 15.9 | 131 504 | 14.9 |
Hawaiian/Pacific Islander | 1253 | 0.1 | 930 | 0.1 |
White | 692 422 | 67.6 | 606 548 | 68.7 |
Other | 118 170 | 11.5 | 101 493 | 11.5 |
Unknown | 19 593 | 1.9 | 18 543 | 2.1 |
Hispanic/Latino | ||||
Yes | 181 966 | 17.8 | 136 414 | 15.5 |
Length of stay | ||||
Mean | 6 | 6 | ||
Median (IQR) | 4 (3.0–6.0) | 4 (3.0–6.0) | ||
Staffed beds | ||||
Mean | 344 | 363 | ||
Median (IQR) | 313 (231–417) | 315 (231–425) | ||
Elixhauser count | ||||
Mean | 3 | 3 | ||
Median (IQR) | 2 (1.0–4.0) | 2 (1.0–4.0) |
Abbreviations: IQR, interquartile range; NHSN, National Healthcare Safety Network.
. | Number of Discharges in 148 NHSN Facilities (N = 1 024 160) . | . | Number of Discharges in 81 Facilities With Microbiology Data (N = 882 835) . | . |
---|---|---|---|---|
Patient characteristic . | N . | % . | N . | % . |
Age at admission | ||||
Mean | 50 | 51 | ||
Median (IQR) | 55 (31.0–72.0) | 56 (31.0–72.0) | ||
Age categorized | ||||
0–17 | 125 613 | 12.3 | 108 961 | 12.3 |
18–44 | 270 397 | 26.4 | 224 274 | 25.4 |
45–54 | 103 017 | 10.1 | 88 142 | 10.0 |
55–64 | 152 037 | 14.8 | 132 238 | 15.0 |
65–74 | 165 925 | 16.2 | 147 004 | 16.7 |
75–84 | 132 897 | 13.0 | 118 009 | 13.4 |
≥85 | 74 265 | 7.3 | 64 197 | 7.3 |
Age >65 | ||||
Yes | 373 087 | 36.4 | 329 210 | 37.3 |
Male | ||||
Yes | 459 221 | 44.8 | 394 537 | 44.7 |
Race categorized | ||||
Asian | 19 829 | 1.9 | 16 037 | 1.8 |
Asian Indian | 8383 | 0.8 | 6278 | 0.7 |
American Indian/ Alaska Native | 1461 | 0.1 | 1502 | 0.2 |
Black | 163 049 | 15.9 | 131 504 | 14.9 |
Hawaiian/Pacific Islander | 1253 | 0.1 | 930 | 0.1 |
White | 692 422 | 67.6 | 606 548 | 68.7 |
Other | 118 170 | 11.5 | 101 493 | 11.5 |
Unknown | 19 593 | 1.9 | 18 543 | 2.1 |
Hispanic/Latino | ||||
Yes | 181 966 | 17.8 | 136 414 | 15.5 |
Length of stay | ||||
Mean | 6 | 6 | ||
Median (IQR) | 4 (3.0–6.0) | 4 (3.0–6.0) | ||
Staffed beds | ||||
Mean | 344 | 363 | ||
Median (IQR) | 313 (231–417) | 315 (231–425) | ||
Elixhauser count | ||||
Mean | 3 | 3 | ||
Median (IQR) | 2 (1.0–4.0) | 2 (1.0–4.0) |
. | Number of Discharges in 148 NHSN Facilities (N = 1 024 160) . | . | Number of Discharges in 81 Facilities With Microbiology Data (N = 882 835) . | . |
---|---|---|---|---|
Patient characteristic . | N . | % . | N . | % . |
Age at admission | ||||
Mean | 50 | 51 | ||
Median (IQR) | 55 (31.0–72.0) | 56 (31.0–72.0) | ||
Age categorized | ||||
0–17 | 125 613 | 12.3 | 108 961 | 12.3 |
18–44 | 270 397 | 26.4 | 224 274 | 25.4 |
45–54 | 103 017 | 10.1 | 88 142 | 10.0 |
55–64 | 152 037 | 14.8 | 132 238 | 15.0 |
65–74 | 165 925 | 16.2 | 147 004 | 16.7 |
75–84 | 132 897 | 13.0 | 118 009 | 13.4 |
≥85 | 74 265 | 7.3 | 64 197 | 7.3 |
Age >65 | ||||
Yes | 373 087 | 36.4 | 329 210 | 37.3 |
Male | ||||
Yes | 459 221 | 44.8 | 394 537 | 44.7 |
Race categorized | ||||
Asian | 19 829 | 1.9 | 16 037 | 1.8 |
Asian Indian | 8383 | 0.8 | 6278 | 0.7 |
American Indian/ Alaska Native | 1461 | 0.1 | 1502 | 0.2 |
Black | 163 049 | 15.9 | 131 504 | 14.9 |
Hawaiian/Pacific Islander | 1253 | 0.1 | 930 | 0.1 |
White | 692 422 | 67.6 | 606 548 | 68.7 |
Other | 118 170 | 11.5 | 101 493 | 11.5 |
Unknown | 19 593 | 1.9 | 18 543 | 2.1 |
Hispanic/Latino | ||||
Yes | 181 966 | 17.8 | 136 414 | 15.5 |
Length of stay | ||||
Mean | 6 | 6 | ||
Median (IQR) | 4 (3.0–6.0) | 4 (3.0–6.0) | ||
Staffed beds | ||||
Mean | 344 | 363 | ||
Median (IQR) | 313 (231–417) | 315 (231–425) | ||
Elixhauser count | ||||
Mean | 3 | 3 | ||
Median (IQR) | 2 (1.0–4.0) | 2 (1.0–4.0) |
Abbreviations: IQR, interquartile range; NHSN, National Healthcare Safety Network.
Increased relative rates of CLABSI, CAUTI, and MRSA bacteremia reported to NHSN were associated with increasing monthly COVID-19 discharges (Table 2). For each 0.1 increase in the monthly number of discharges of COVID-19 patients per staffed bed, there was a relative increase of 1.14 (95% confidence interval [CI], 1.09–1.19) for CLABSI, 1.09 (95% CI: 1.04–1.15) for CAUTI, and 1.09 (95% CI: 1.04–1.14) for MRSA bacteremia (Figure 2a–2c). Larger hospital size was independently associated with a greater number of HAI events. Over 7 months, there were 60% (95% CI: 23–108%) more CLABSI, 43% (95% CI: 8–90%) more CAUTI, and 44% (95% CI: 10–88%) more cases of MRSA bacteremia than were expected based on the predicted number across the 148 hospitals. CDI relative rates, however, were not associated with increased monthly rates of COVID-19 discharges, 0.97 (95% CI: .93–1.02) (Figure 2d).
Effect of an Increase in Number of COVID-19 Discharges on HAIs and Hospital-Onset Pathogens
Event . | Effect . | Total . | Median (IQR) . | Relative Rate (95% CI) . | P value . |
---|---|---|---|---|---|
CLABSI | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 440 | 0 (0–1) | 1.14 (1.09, 1.19) | <.001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 2.14 (1.42, 3.23) | <.001 | |||
Beds ≥300 | 2.43 (1.66, 3.56) | <.001 | |||
CAUTI | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 282 | 0 (0–0) | 1.09 (1.04, 1.15) | .001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 2.13 (1.39, 3.28) | .001 | |||
Beds ≥300 | 1.91 (1.27, 2.87) | .002 | |||
CDI | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 658 | 0 (0–1) | 0.97 (0.93, 1.02) | .247 |
Beds <200 | Ref | . | |||
Beds 200–299 | 3.37 (2.29, 4.96) | <.001 | |||
Beds ≥300 | 3.17 (2.00, 5.01) | <.001 | |||
MRSA BSI | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 298 | 0 (0–0) | 1.09 (1.04, 1.14) | .001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 2.05 (1.28, 3.28) | .003 | |||
Beds ≥300 | 2.18 (1.26, 3.76) | .005 | |||
BSI | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 2911 | 2 (1–5) | 1.05 (1.03, 1.07) | <.001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 3.19 (2.37, 4.30) | <.001 | |||
Beds ≥300 | 7.03 (5.29, 9.34) | <.001 | |||
MDRO | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 5097 | 5 (2–9) | 1.05 (1.04, 1.07) | <.001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 3.01 (2.31, 3.93) | <.001 | |||
Beds ≥300 | 5.44 (4.21, 7.03) | <.001 | |||
MRSA | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 1944 | 2 (0–3) | 1.06 (1.04, 1.08) | <.001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 2.79 (2.02, 3.87) | <.001 | |||
Beds ≥300 | 4.44 (3.25, 6.07) | <.001 | |||
VRE | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 583 | 0 (0–1) | 1.04 (1.01, 1.08) | .016 |
Beds <200 | Ref | . | |||
Beds 200–299 | 2.88 (1.75, 4.75) | <.001 | |||
Beds ≥300 | 5.05 (3.13, 8.13) | <.001 | |||
GNR | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 2849 | 2 (1–5) | 1.06 (1.04, 1.08) | <.001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 3.16 (2.35, 4.26) | <.001 | |||
Beds ≥300 | 6.29 (4.73, 8.37) | <.001 | |||
Clusters | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 101 | 0 (0–0) | 1.09 (1.01, 1.18) | .02 |
Beds <200 | Ref | . | |||
Beds 200–299 | 1.55 (0.74, 3.27) | 0.25 | |||
Beds ≥300 | 3.17 (1.63, 6.17) | <.001 |
Event . | Effect . | Total . | Median (IQR) . | Relative Rate (95% CI) . | P value . |
---|---|---|---|---|---|
CLABSI | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 440 | 0 (0–1) | 1.14 (1.09, 1.19) | <.001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 2.14 (1.42, 3.23) | <.001 | |||
Beds ≥300 | 2.43 (1.66, 3.56) | <.001 | |||
CAUTI | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 282 | 0 (0–0) | 1.09 (1.04, 1.15) | .001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 2.13 (1.39, 3.28) | .001 | |||
Beds ≥300 | 1.91 (1.27, 2.87) | .002 | |||
CDI | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 658 | 0 (0–1) | 0.97 (0.93, 1.02) | .247 |
Beds <200 | Ref | . | |||
Beds 200–299 | 3.37 (2.29, 4.96) | <.001 | |||
Beds ≥300 | 3.17 (2.00, 5.01) | <.001 | |||
MRSA BSI | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 298 | 0 (0–0) | 1.09 (1.04, 1.14) | .001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 2.05 (1.28, 3.28) | .003 | |||
Beds ≥300 | 2.18 (1.26, 3.76) | .005 | |||
BSI | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 2911 | 2 (1–5) | 1.05 (1.03, 1.07) | <.001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 3.19 (2.37, 4.30) | <.001 | |||
Beds ≥300 | 7.03 (5.29, 9.34) | <.001 | |||
MDRO | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 5097 | 5 (2–9) | 1.05 (1.04, 1.07) | <.001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 3.01 (2.31, 3.93) | <.001 | |||
Beds ≥300 | 5.44 (4.21, 7.03) | <.001 | |||
MRSA | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 1944 | 2 (0–3) | 1.06 (1.04, 1.08) | <.001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 2.79 (2.02, 3.87) | <.001 | |||
Beds ≥300 | 4.44 (3.25, 6.07) | <.001 | |||
VRE | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 583 | 0 (0–1) | 1.04 (1.01, 1.08) | .016 |
Beds <200 | Ref | . | |||
Beds 200–299 | 2.88 (1.75, 4.75) | <.001 | |||
Beds ≥300 | 5.05 (3.13, 8.13) | <.001 | |||
GNR | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 2849 | 2 (1–5) | 1.06 (1.04, 1.08) | <.001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 3.16 (2.35, 4.26) | <.001 | |||
Beds ≥300 | 6.29 (4.73, 8.37) | <.001 | |||
Clusters | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 101 | 0 (0–0) | 1.09 (1.01, 1.18) | .02 |
Beds <200 | Ref | . | |||
Beds 200–299 | 1.55 (0.74, 3.27) | 0.25 | |||
Beds ≥300 | 3.17 (1.63, 6.17) | <.001 |
Abbreviations: BSI, bloodstream infections; CI, confidence interval; CAUTI, catheter-associated urinary tract infections; CDI, Clostridioides difficile infections; CLABSI, central line-associated blood stream infections; COVID-19, coronavirus disease 2019; GNR, gram-negative rod; IQR, interquartile range; MDRO, multidrug-resistant organisms; MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococcus.
Effect of an Increase in Number of COVID-19 Discharges on HAIs and Hospital-Onset Pathogens
Event . | Effect . | Total . | Median (IQR) . | Relative Rate (95% CI) . | P value . |
---|---|---|---|---|---|
CLABSI | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 440 | 0 (0–1) | 1.14 (1.09, 1.19) | <.001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 2.14 (1.42, 3.23) | <.001 | |||
Beds ≥300 | 2.43 (1.66, 3.56) | <.001 | |||
CAUTI | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 282 | 0 (0–0) | 1.09 (1.04, 1.15) | .001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 2.13 (1.39, 3.28) | .001 | |||
Beds ≥300 | 1.91 (1.27, 2.87) | .002 | |||
CDI | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 658 | 0 (0–1) | 0.97 (0.93, 1.02) | .247 |
Beds <200 | Ref | . | |||
Beds 200–299 | 3.37 (2.29, 4.96) | <.001 | |||
Beds ≥300 | 3.17 (2.00, 5.01) | <.001 | |||
MRSA BSI | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 298 | 0 (0–0) | 1.09 (1.04, 1.14) | .001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 2.05 (1.28, 3.28) | .003 | |||
Beds ≥300 | 2.18 (1.26, 3.76) | .005 | |||
BSI | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 2911 | 2 (1–5) | 1.05 (1.03, 1.07) | <.001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 3.19 (2.37, 4.30) | <.001 | |||
Beds ≥300 | 7.03 (5.29, 9.34) | <.001 | |||
MDRO | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 5097 | 5 (2–9) | 1.05 (1.04, 1.07) | <.001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 3.01 (2.31, 3.93) | <.001 | |||
Beds ≥300 | 5.44 (4.21, 7.03) | <.001 | |||
MRSA | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 1944 | 2 (0–3) | 1.06 (1.04, 1.08) | <.001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 2.79 (2.02, 3.87) | <.001 | |||
Beds ≥300 | 4.44 (3.25, 6.07) | <.001 | |||
VRE | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 583 | 0 (0–1) | 1.04 (1.01, 1.08) | .016 |
Beds <200 | Ref | . | |||
Beds 200–299 | 2.88 (1.75, 4.75) | <.001 | |||
Beds ≥300 | 5.05 (3.13, 8.13) | <.001 | |||
GNR | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 2849 | 2 (1–5) | 1.06 (1.04, 1.08) | <.001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 3.16 (2.35, 4.26) | <.001 | |||
Beds ≥300 | 6.29 (4.73, 8.37) | <.001 | |||
Clusters | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 101 | 0 (0–0) | 1.09 (1.01, 1.18) | .02 |
Beds <200 | Ref | . | |||
Beds 200–299 | 1.55 (0.74, 3.27) | 0.25 | |||
Beds ≥300 | 3.17 (1.63, 6.17) | <.001 |
Event . | Effect . | Total . | Median (IQR) . | Relative Rate (95% CI) . | P value . |
---|---|---|---|---|---|
CLABSI | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 440 | 0 (0–1) | 1.14 (1.09, 1.19) | <.001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 2.14 (1.42, 3.23) | <.001 | |||
Beds ≥300 | 2.43 (1.66, 3.56) | <.001 | |||
CAUTI | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 282 | 0 (0–0) | 1.09 (1.04, 1.15) | .001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 2.13 (1.39, 3.28) | .001 | |||
Beds ≥300 | 1.91 (1.27, 2.87) | .002 | |||
CDI | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 658 | 0 (0–1) | 0.97 (0.93, 1.02) | .247 |
Beds <200 | Ref | . | |||
Beds 200–299 | 3.37 (2.29, 4.96) | <.001 | |||
Beds ≥300 | 3.17 (2.00, 5.01) | <.001 | |||
MRSA BSI | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 298 | 0 (0–0) | 1.09 (1.04, 1.14) | .001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 2.05 (1.28, 3.28) | .003 | |||
Beds ≥300 | 2.18 (1.26, 3.76) | .005 | |||
BSI | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 2911 | 2 (1–5) | 1.05 (1.03, 1.07) | <.001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 3.19 (2.37, 4.30) | <.001 | |||
Beds ≥300 | 7.03 (5.29, 9.34) | <.001 | |||
MDRO | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 5097 | 5 (2–9) | 1.05 (1.04, 1.07) | <.001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 3.01 (2.31, 3.93) | <.001 | |||
Beds ≥300 | 5.44 (4.21, 7.03) | <.001 | |||
MRSA | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 1944 | 2 (0–3) | 1.06 (1.04, 1.08) | <.001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 2.79 (2.02, 3.87) | <.001 | |||
Beds ≥300 | 4.44 (3.25, 6.07) | <.001 | |||
VRE | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 583 | 0 (0–1) | 1.04 (1.01, 1.08) | .016 |
Beds <200 | Ref | . | |||
Beds 200–299 | 2.88 (1.75, 4.75) | <.001 | |||
Beds ≥300 | 5.05 (3.13, 8.13) | <.001 | |||
GNR | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 2849 | 2 (1–5) | 1.06 (1.04, 1.08) | <.001 |
Beds <200 | Ref | . | |||
Beds 200–299 | 3.16 (2.35, 4.26) | <.001 | |||
Beds ≥300 | 6.29 (4.73, 8.37) | <.001 | |||
Clusters | Per 0.1 increase in the monthly number of COVID-19 discharges per staffed bed | 101 | 0 (0–0) | 1.09 (1.01, 1.18) | .02 |
Beds <200 | Ref | . | |||
Beds 200–299 | 1.55 (0.74, 3.27) | 0.25 | |||
Beds ≥300 | 3.17 (1.63, 6.17) | <.001 |
Abbreviations: BSI, bloodstream infections; CI, confidence interval; CAUTI, catheter-associated urinary tract infections; CDI, Clostridioides difficile infections; CLABSI, central line-associated blood stream infections; COVID-19, coronavirus disease 2019; GNR, gram-negative rod; IQR, interquartile range; MDRO, multidrug-resistant organisms; MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococcus.

Predicted mean HAI rates as COVID-19 discharges increase. Predicted mean HAI rate by increasing monthly COVID-19 discharges. a, CLABSI; b, CAUTI; c, MRSA bacteremia; d, CDI. Data are stratified by small, medium, and large hospitals. Abbreviations: CAUTI, catheter-associated urinary tract infections; CLABSI, central line-associated blood stream infections; COVID-19, coronavirus disease 2019; HAI, healthcare-associated infection; MRSA, methicillin-resistant Staphylococcus aureus.
When evaluating microbiology data from the subset of 81 hospitals, there was a greater absolute number of hospital-onset BSIs and MDRO-positive cultures associated with an increase in the number of COVID-19 hospitalizations. Per 0.1 increase in the monthly number of discharges of COVID-19 patients per staffed bed, the relative rate was 1.05 (95% CI, 1.03–1.07) for hospital-onset BSIs and 1.05 (95% CI: 1.04–1.07) for any hospital-onset MDRO. Specific MDRO rates included a relative increase of 1.06 (95% CI: 1.04–1.08) for hospital-onset MRSA, 1.04 (95% CI: 1.01–1.08) for hospital-onset VRE, and 1.06 (95% CI: 1.04–1.08) for hospital-onset multidrug resistant Gram-negative bacteria (Table 2). Hospital size was also independently associated with BSI and MDRO events. Chronologic calendar month and use of contact precautions for MRSA and VRE were not found to be statistically significant and were not included in the final model. Over 10 months, 882 835 discharges experienced an additional 24% (95% CI: 2–51%) of hospital-onset BSIs and 24% (95% CI: 3–49%) of hospital-onset MDROs than predicted, including 30% (95% CI: 4–63%) hospital-onset MRSA, 44% (95% CI: 3–102%) hospital-onset VRE, and 27% (95% CI, 4–55%) hospital-onset multidrug resistant Gram-negative organisms that were temporally associated with COVID-19 surges.
Spatiotemporal scanning in 40 hospitals identified 101 clusters with a mean size of 3.8 isolates. Increased relative rates of clusters of hospital-onset pathogens were associated with increasing monthly rates of COVID-19 discharges per staffed bed. For each increase of 0.1 in the monthly number of discharges of COVID-19 patients per staffed bed, there was a relative increase of 1.09 (95% CI: 1.01–1.18) in the occurrence of clusters (Table 2, Figure 3). The cluster isolates accounted for 16% of the excess BSI cases and 36% of the excess MDRO cases.

Monthly comparison of COVID discharges to clusters. COVID-19 discharges and the number of clusters of hospital-onset pathogens are correlated throughout the pandemic. Abbreviation: COVID-19, coronavirus disease 2019.
Discussion
This analysis of prospectively collected HAI and microbiology data in geographically diverse US hospitals confirmed that elevated HAI rates were temporally associated with increases in hospitalized COVID-19 patients. Furthermore, the number of clusters of hospital-onset pathogens increased during COVID-19 surges, suggesting increased healthcare-associated transmission as one possible mechanism to account for increases in HAIs. As the facilities included here represent a sample of hospitals across the United States with varying local pandemic pressures, this analysis supports the hypothesis that certain HAI rates are being adversely affected by the pandemic response. This highlights the critical importance of identifying strategies to ensure the sustainability of routine infection prevention programs even during periods of public health crises that require diversion of healthcare resources.
In the HCA healthcare system and many other hospitals, HAI rates had been steadily declining prior to the COVID-19 pandemic [16]. Efforts in hospitals to reach zero HAIs focused attention on surveillance and infection prevention process measures [17]. However, as health systems were strained by COVID-19, HAI rates increased, demonstrating how community pandemic control impacts other patients beyond those infected by the pandemic pathogen. This study’s finding that the number of clusters significantly increased is consistent with recent case reports of outbreaks during COVID-19 surges or on COVID-19 specialty units [18, 19]. The additional burden of COVID-19 care, disrupting routine practice, may have contributed to the clustering of infections, including both lapses in routine infection prevention practice as well as transmission of healthcare-associated pathogens. Additionally, during COVID-19 surges, many elective admissions were canceled, resulting in higher acuity patient populations [20].
As our analysis and others have shown, CDI rates were stable or decreased during the COVID-19 pandemic [21]. Barrier precautions and increased training on donning and doffing of PPE to prevent COVID-19 transmission might have led to reductions in the carriage of C. difficile. This may have been particularly important for reducing transmission of C. difficile spores, which are often resistant to alcohol-based hand sanitizer and may survive on surfaces for extended periods of time. Alternatively, rates of CDI may lag due to the delayed consequences of changes in antimicrobial stewardship or changes in testing practices.
Limitations of this study include use of NHSN-reported HAI events. Variations in surveillance and reporting may affect NHSN HAI data, especially when infection prevention activities are constrained. Some facilities may have been challenged, leading to reduced reporting whereas other facilities may have noted heightened vigilance leading to increased reporting. However, this study supplements NHSN reported events dependent on adjudication, such as CLABSI or CAUTI, with microbiology-based analyses that minimize the potential impact of reduced infection preventionist effort available for HAI surveillance. Additionally, HAI rates may have been impacted by dynamic changes in the overall risk of HAIs within the inpatient population given the marked increase in acuity and decrease in elective admissions.
Although the per-patient risk of a hospital-onset infection remained very low, HAI rates increased during COVID-19 surges. Further research is necessary to elucidate the specific ways in which the COVID-19 burden is affecting HAI rates, but our results identify a need to build capacity in infection prevention and control. As hospitals and healthcare systems prepare for the next stages of the pandemic and recovery, this study emphasizes the need to remain focused on routine infection prevention.
Notes
Financial support. This work was supported by the Centers for Disease Control and Prevention Epicenters Program (grant number CDC RFA-CK-16-004).
Potential conflicts of interest. D. Y. reports being a member of the Society for Healthcare Epidemiology of America (SHEA) Board of Trustees, unpaid. J. B. P. reports being a shareholder and employee of HCA Healthcare. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
References
Author notes
M. A. B. and K. E. S. contributed equally to this work.